TOG Review (RCOG Journal)
MRCOG Part 2
Subfertility and Reproductive Medicine
New technologies for the management of ovarian ageing
Key Statistics
- 1–2 million — Primordial follicles at birth
- ~1000 — Follicles remaining at menopause
- 60% / 18.4% — Pregnancy rate / cumulative LBR, ovarian fragmentation in POI
Don't-miss facts
-
Egg donation is the only POI treatment with established clinical effectiveness – all technologies below are experimental/not regulator-approved
-
Ovarian fragmentation (no stimulation) in POI: pregnancy rate up to 60%, cumulative LBR 18.4%
-
G-CSF-stimulated autologous bone marrow: 81.3% improved ovarian function, 29% pregnancy rate, but does not correct aneuploidy
-
PRP: pooled pregnancy rate 22%; RCT shows no gain in euploid blastocysts/term pregnancy despite more mature oocytes
-
Maternal spindle transfer: 6/28 (21%) livebirths – latest mitochondrial replacement technique, avoids heteroplasmy
-
CoQ10 pre-treatment: clinical pregnancy rate 28.8% vs 14.1% but no livebirth/miscarriage benefit (surrogate outcome trap)
-
Quantity-targeting techniques (IVG, follicular activation, stem cell, PRP, artificial ovary) vs quality-targeting techniques (mitochondrial replacement, gene editing, senotherapies)
Quantity vs quality – therapeutic targets
Quantity: IVG · follicular activation · stem cell · PRP · artificial ovary
Quality: mitochondrial replacement · gene editing (CRISPR-Cas9) · senotherapies
Abbreviation Key
- POI — premature ovarian insufficiency
- S1P — sphingosine-1-phosphate
- AGE — advanced glycation end products
- IGF-1 — insulin-like growth factor 1
- ROS — reactive oxygen species
- NAD/NADH — nicotinamide adenine dinucleotide (oxidised/reduced)
- iPSC — induced pleuripotent stem cell
- NMN — nicotinamide mononucleotide
- CRISPR-Cas9 — clustered regularly interspaced short palindromic
- NR — nicotinamide riboside repeats – CRISPR associated protein 9 (gene-editing nuclease)
- CoQ10 — coenzyme Q10
- PRP — platelet-rich plasma
- LBR — livebirth rate
- G-CSF — granulocyte colony-stimulating factor
- ATP — adenosine triphosphate
- VEGF — vascular endothelial growth factor
- MII — metaphase II (oocyte)
- PDGF-AB — platelet-derived growth factor AB
- IVF — in vitro fertilisation
- TGF — transforming growth factor
- Akt — protein kinase B
Source: Woon EV, Ibeto L, Nikolaou D. New technologies for the management of ovarian ageing. The Obstetrician & Gynaecologist 2025;27:136–141. doi:10.1111/tog.12972
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).